Weekly Top News – Psoriasis – August 5, 2019

August 5, 2019

Siliq (brodalumab) / Bausch Health, Leo Pharma, Kyowa Hakko Kirin
Brodalumab: Regulatory decision in Asia for psoriasis in 2020 (Kyowa Hakko Kirin Pharma) – Aug 2, 2019 – Q2 2019 Results  
[Screenshot]

 

Ilumya (tildrakizumab-asmn) / Sun Pharma, Almirall
Sun Pharma announces regulatory filing of tildrakizumab in Japan; stock down 1.5% (IIFL) – Aug 1, 2019 – “The co. announced that one of its wholly owned subsidiaries has filed an application for Manufacturing and Marketing Authorization of Tildrakizumab for moderate-to-severe psoriasis and psoriatic arthritis with the Pharmaceuticals and Medical Devices Agency (PMDA), Japan.”

 

PF-06700841 / Pfizer
A PHASE 2B DOSE RANGING STUDY TO ASSESS EFFICACY, SAFETY, TOLERABILITY AND PHARMACOKINETICS OF PF-06700841 TOPICAL CREAM IN PARTICIPANTS WITH CHRONIC PLAQUE PSORIASIS (clinicaltrialsregister.eu) – Aug 1, 2019 – P2; N=240; Ongoing; Sponsor: Pfizer Inc.

 

piclidenoson (CF101) / Can-Fite, China Medical System
Can-Fite signs agreement with Kyongbo Pharm for the distribution in South Korea of piclidenoson in the treatment of psoriasis (Can-Fite Biopharma Press Release) – Aug 1, 2019 – “Can-Fite BioPharma…today announced it has signed a distribution agreement with Kyongbo Pharm Co., Ltd., to distribute Can-Fite’s lead drug candidate, Piclidenoson (CF101), for the treatment of psoriasis in South Korea, upon receipt of regulatory approvals….Up to $4,000,000 in upfront and milestone payments, plus a transfer price for delivering finished product…”

 

ANB019 / AnaptysBio
ANB019 US pricing projection: $50,000/year (Credit Suisse) – Jul 29, 2019 – A subscription to Thomson ONE is required to gain full access to report 67407578; Page no: 6; REPORT TITLE: “Anaptysbio Inc ANAB: Bull versus bear debate”; AUTHOR: Auster, Martin, et al; DATE: 05/29/2019

 

Cosentyx (secukinumab) / Novartis
Cosentyx sales projection: $4.9B in 2023 (Kepler Cheuvreux) – Aug 3, 2019 – A subscription to Thomson ONE is required to gain full access to report 67665572; Page no: 8; REPORT TITLE: “Novartis AG – Espresso note | Novartis | Hold | Great business, fair value: downgrade to Hold”; AUTHOR: Evans, David, et al; DATE: 07/23/2019

 

Ilumya (tildrakizumab-asmn) / Sun Pharma, Almirall; Skilarence (dimethyl fumarate) / Almirall
Almirall H1 2019 – Continued strong business momentum while reinforcing pipeline (Almirall Press Release) – Jul 29, 2019 – “Research & Development costs were €43.9 MM in H1, representing 10.2% of Net Sales (vs. 9.7% of Net Sales in Q1 2019 and 10.4% in H1 2018) due to Phase IV studies for Skilarence® and Ilumetri….Rollout of Ilumetri is ongoing, achieving a solid unit sales growth (+63% unit growth) during Q2 2019 in Germany, the UK and some Nordic Countries….Rollout continues in H2 with The Netherlands, Austria, Spain, Ireland, Poland and additionally Switzerland, following positive recommendations by Swissmedic….Skilarence® has delivered €16 MM of sales, representing over 102% year-on-year Net Sales growth vs. H1 2018.”

No Comments

Post a Comment

Comment
Name
Email
Website